November 12th 2024
The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.
November 7th 2024
The study outcomes were estimated IMD cases and deaths averted by MenACWY vaccination in adolescents and adults aged 11 to 23 years.
October 28th 2024
"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.
October 24th 2024
Donna Hallas, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights key takeaways from our October Vaccine issue of Contemporary Pediatrics.
Infants, young children, and older adults are at the highest risk for pneumococcal infection, and viral illnesses, such as influenza, may predispose sensitive groups to pneumococcal infection.
Pfizer and BioNTech request Emergency Use Authorization for Omicron booster
Pfizer and BioNTech have applied to the FDA for Emergency Use Authorization of their Omicron BA.4/BA.5-adapted bivalent vaccine booster for use in pediatric patients aged 3 to 11 years.
Influenza effects and prevention in children
In a recent report, the American Academy of Pediatrics discussed how influenza affects children and how it can be prevented.
COVID-19 vaccine associated with increased menstrual cycle length
In a recent study, participants who had received a COVID-19 vaccine saw an average increase in menstrual cycle length of less than 1 day.
Take-Home Points About COVID-19 Vaccines for Pediatric Patients
Dr Muller and Dr Offit provide take-home messages about COVID-19 vaccines for pediatric patients.
Coadministration of Vaccines for Children Younger Than 5 Years
Expert pediatricians discuss challenges with coadministration of vaccines in children younger than 5 years.
Hepatitis B risks vs vaccine risks
In 2 new education documents, Physicians for Informed Consent outlines the risks of Hepatitis B compared to the risks of the Hepatitis B vaccination.
Maternal vaccination reduces risk of infant COVID-19 hospitalization
Infants of fully vaccinated mothers had fewer cases of hospitalization from COVID-19 than those unvaccinated.
Developments in COVID-19 Vaccines for Children Younger Than 5 Years
Dr Muller and Dr Offit discuss recent developments in the COVID-19 vaccine for children younger than 5 years.
The Effect of COVID-19 Variants on Vaccines for Children
Dr Muller and Dr Offit discuss COVID-19 variants and their effect on vaccine development.
CDC recommends updated COVID-19 boosters ahead of possible fall surge
Move comes after FDA give emergency use authorization for bivalent vaccines.
COVID-19 vaccination reduces risk of adverse maternal-fetal outcomes
In a recent study, investigators found lower rates of COVID-19 infection and other adverse outcomes in vaccinated pregnant people over those unvaccinated.
FDA approves ‘updated boosters’ to fight COVID-19 omicron variants
Latest emergency use authorizations for Moderna, Pfizer-BioNTech vaccines.
The Impact of the COVID-19 Vaccine on Spread of Disease
Paul A. Offit, MD, comments on spread of the COVID-19 virus in children who are vaccinated.
Addressing Vaccine Hesitancy
Vaccine and infectious disease experts address vaccine hesitancy and the importance of the COVID-19 vaccine in children.
The Impact of COVID-19 on Children
William J. Muller, MD, PhD; and Paul A. Offit, MD, discuss the impact of COVID-19 on children.
Differences in Response to Vaccines in Children Compared to Adults
Drs William J. Muller and Paul A. Offit discuss differences in response to vaccines in children compared to adults.
FDA grants emergency use of Novavax COVID-19 vaccine, adjuvanted in patients 12 years and older
Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen
Parents express low confidence in pediatric COVID-19 vaccine
Only one-fifth of parents in a recent survey indicated intentions of getting their child the vaccine within 3 months of eligibility.
What's coming in the 2022-2023 flu season
Learn about the selected strains for this year’s flu season, flu vaccine recommendation changes, and newly licensed and forthcoming vaccine options.
Amid decline in immunizations, AAP urges parents to keep up to date with child vaccinations
As immunization rates fall in children, the American Academy of Pediatrics recommends a checkup with physicians.
HHS orders at least 105 million doses of COVID-19 vaccine for fall
Purchase follows FDA recommendation to include Omicron component in boosters.
Pfizer-BioNTech vaccine efficacy against Omicron in children 5-11 years
In children 5-11 years old, 2 doses of the Pfizer-BioNTech COVID-19 vaccine were moderately effective against documented, symptomatic Omicron infection.
Against COVID-19, both natural and vaccination-mediated protection wane over time
Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.
AAP launches PSA on COVID-19 vaccine education for youngest children
Recently, the AAP announced the launch of a public health campaign to educate caregivers on the benefits of vaccinating all ages.
FDA approves Merck pneumococcal 15-valent conjugate vaccine for ages 6 weeks through 17 years
The FDA today approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.
FDA authorizes Moderna, Pfizer-BioNTech COVID-19 vaccines for children down to 6 months of age
The FDA today announces the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.
PRIORIX FDA approval expands supply of MMR vaccines
In a video for Contemporary Pediatrics®, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses an expansion of vaccine access likely to come with the FDA approval of the PRIORIX vaccine.
FDA approves PRIORIX for measles, mumps, and rubella prevention
GSK plc today announced FDA approval of the PRIORIX vaccine for prevention of measles, mumps, and rubella.
Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years
Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children
Vaccines in development: What we can look forward to in preventing infectious diseases
What we can look forward to in preventing infectious diseases.